Evolent Health, Inc. EVH
4.80 USD +0.09 (+1.91%)
At closeNov 10, 2026, 4:00 PM EST
4.80 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
4.57 Day range 4.91
2.10 52-week range 6.26
- YTD
- +20.00%
- 1 year
- -3.03%
News
benzinga.com Why Is Humana Stock Trading Higher Tuesday? Humana (HUM) stock jumped over 3% following a new cancer care initiative and a raised 2026 earnings outlook. Read the latest updates.
benzinga.com Humana Partners With Evolent Health, American Oncology Network To Introduce New Cancel Care Model In 8 U.S. States Humana Inc., in collaboration with Evolent Health, Inc. and American Oncology Network (AON), today announced the launch of a new cancer care model designed to improve the quality, timeliness and…
seekingalpha.com Evolent Health, Inc. (EVH) Q3 2026 Earnings Call Transcript Evolent Health, Inc. ( EVH ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Seth Blackley - Co-Founder, CEO & Director Mario Ramos - Chief Financial Officer Conference Call…
marketbeat.com What Evolent Health (EVH) Said on Its Q3 Earnings Call Evolent Health NYSE: EVH raised the lower end of its 2026 adjusted earnings outlook after third-quarter revenue and profitability improved from the preceding quarter, helped by growth in its…
benzinga.com Oppenheimer Maintains Outperform on Evolent Health, Raises Price Target to $7 Oppenheimer analyst Michael Wiederhorn maintains Evolent Health (NYSE:EVH) with a Outperform and raises the price target from $6 to $7.
benzinga.com Needham Maintains Buy on Evolent Health, Raises Price Target to $6 Needham analyst Matthew Shea maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $5 to $6.
zacks.com Evolent Health (EVH) Matches Q3 Earnings Estimates Evolent Health (EVH) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.05 per share a year ago.
zacks.com Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key…
benzinga.com Evolent Health Q3 2026 Earnings Call Transcript Evolent Health (NYSE:EVH) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…- benzinga.com Evolent Health Affirms FY2026 Sales Guidance of $2.600B-$2.700B vs $2.626B Est Evolent Health (NYSE:EVH) affirms FY2026 sales outlook from $2.600 billion-$2.700 billion to $2.600 billion-$2.700 billion vs $2.626 billion estimate.
benzinga.com Evolent Health Q3 Adj. EPS $0.06 Beats $0.05 Estimate, Sales $725.367M Beat $724.186M Estimate Evolent Health (NYSE:EVH) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.05 by 20 percent. This is a 20 percent increase over earnings of $0.05 per…
prnewswire.com Evolent Announces Third Quarter 2026 Results WASHINGTON, Nov. 5, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through…
defenseworld.net Analyzing CareCloud (NASDAQ:CCLD) & Evolent Health (NYSE:EVH) Evolent Health (NYSE: EVH - Get Free Report) and CareCloud (NASDAQ: CCLD - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses…
prnewswire.com Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026 WASHINGTON, Oct. 9, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release…
defenseworld.net Evolent Health, Inc (NYSE:EVH) Receives Consensus Recommendation of “Moderate Buy” from Brokerages Evolent Health, Inc (NYSE: EVH - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the sixteen ratings firms that are covering the company, Marketbeat Ratings reports.…
globenewswire.com TransPerfect Selected by Evolent for Enterprise-Wide Telephonic Interpretation TransPerfect expands its Evolent partnership to provide enterprise-wide telephonic interpretation and strengthen language access for health plan members.
benzinga.com JP Morgan Maintains Overweight on Evolent Health, Raises Price Target to $6 JP Morgan analyst John Stansel maintains Evolent Health (NYSE:EVH) with a Overweight and raises the price target from $5 to $6.
benzinga.com TD Cowen Maintains Buy on Evolent Health, Raises Price Target to $6 TD Cowen analyst Charles Rhyee maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $5 to $6.
seekingalpha.com Evolent Health Q2 Earnings Review: Debt Is Distressing, But Business Is Booming Evolent Health, Inc. is awarded a contrarian Buy rating despite extreme indebtedness and recent net losses. EVH trades at a deeply distressed valuation (~0.2x forward sales) due to ~$967m long-term…
defenseworld.net Dimensional Fund Advisors LP Has $4.08 Million Stock Position in Evolent Health, Inc $EVH Dimensional Fund Advisors LP reduced its stake in Evolent Health, Inc (NYSE: EVH) by 22.4% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange…- benzinga.com Truist Securities Maintains Hold on Evolent Health, Lowers Price Target to $6 Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Hold and lowers the price target from $7 to $6.
- benzinga.com Citigroup Upgrades Evolent Health to Buy, Lowers Price Target to $6 Citigroup analyst Daniel Grosslight upgrades Evolent Health (NYSE:EVH) from Neutral to Buy and lowers the price target from $6.75 to $6.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers P3 Health Partners (NASDAQ:PIII) shares increased by 24.1% to $15.92 during Monday's after-market session. The market value of their outstanding shares is at $38.5 million. As per the press…
benzinga.com Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $6 Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $7 to $6.
marketbeat.com Evolent Health Q2 Earnings Call Highlights Evolent Health NYSE: EVH reported second-quarter revenue of $653 million, up 31% from the first quarter, and adjusted EBITDA of $28 million, up 27% sequentially, as the company benefited from the May…
seekingalpha.com Evolent Health, Inc. (EVH) Q2 2026 Earnings Call Transcript Evolent Health, Inc. (EVH) Q2 2026 Earnings Call Transcript
zacks.com Compared to Estimates, Evolent Health (EVH) Q2 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics…
zacks.com Evolent Health (EVH) Tops Q2 Earnings and Revenue Estimates Evolent Health (EVH) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to a loss of $0.1 per share a year ago.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's pre-market session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…- benzinga.com Evolent Health Raises FY2026 Sales Guidance from $2.400B-$2.600B to $2.600B-$2.700B vs $2.503B Est Evolent Health (NYSE:EVH) raises FY2026 sales outlook from $2.400 billion-$2.600 billion to $2.600 billion-$2.700 billion vs $2.503 billion estimate.
benzinga.com Evolent Health Q2 Adj. EPS $0.02 Beats $(0.02) Estimate, Sales $652.520M Beat $597.997M Estimate Evolent Health (NYSE:EVH) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.02) by 200 percent. This is a 120 percent increase over losses of $(0.10) per…
prnewswire.com Evolent Announces Second Quarter 2026 Results WASHINGTON, Aug. 6, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through…- benzinga.com TD Cowen Maintains Buy on Evolent Health, Lowers Price Target to $5 TD Cowen analyst Charles Rhyee maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $8 to $5.
- benzinga.com Citigroup Downgrades Evolent Health to Neutral, Raises Price Target to $6.75 Citigroup analyst Daniel Grosslight downgrades Evolent Health (NYSE:EVH) from Buy to Neutral and raises the price target from $5.5 to $6.75.
benzinga.com Canaccord Genuity Maintains Buy on Evolent Health, Raises Price Target to $7 Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $6 to $7.
marketwatch.com Forget Nvidia. These 5 S&P 500 stocks are quietly going all in on AI. The “Mag Seven” has become the “Bag Seven.” Sharp tech investors are looking elsewhere.
zacks.com Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now Healthcare IT is emerging as AI's next growth story as providers adopt AI to cut costs & improve care. Here we present three stocks that are likely to benefit.
prnewswire.com Evolent To Release Second Quarter 2026 Financial Results on Thursday, August 6, 2026 WASHINGTON, July 8, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release…
zacks.com Should You Buy Evolent Health (EVH) After Golden Cross? Evolent Health, Inc (EVH) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, EVH's 50-day simple moving average crossed above…- benzinga.com Truist Securities Downgrades Evolent Health to Hold, Maintains Price Target to $7 Truist Securities analyst Jailendra Singh downgrades Evolent Health (NYSE:EVH) from Buy to Hold and maintains the price target from $7 to $7.
- benzinga.com Truist Securities Maintains Buy on Evolent Health, Raises Price Target to $7 Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $6 to $7.
benzinga.com Rumble, Agilon Health And Oscar Health Among Stocks Moving Higher On Thursday Stocks had mixed performance on Thursday, Dow Jones up 793 points while Nasdaq down 232 points. Rumble rose after $270M deal.- benzinga.com Citigroup Maintains Buy on Evolent Health, Raises Price Target to $5.5 Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $4 to $5.5.
- benzinga.com Needham Maintains Buy on Evolent Health, Raises Price Target to $5 Needham analyst Matthew Shea maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $4 to $5.
- benzinga.com Evolent Health Affirms FY2026 Sales Guidance of $2.400B-$2.600B vs $2.487B Est. Evolent Health (NYSE:EVH) affirms FY2026 sales outlook from $2.400 billion-$2.600 billion to $2.400 billion-$2.600 billion vs $2.487 billion estimate.
- benzinga.com Evolent Health Q1 Adj. EPS $(0.02) Beats $(0.05) Estimate, Sales $496.246M Miss $534.669M Estimate. Evolent Health (NYSE:EVH) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.05) by 60 percent. This is a 133.33 percent decrease over earnings of $0.06…
benzinga.com XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acquire XOMA for $39.00/share. Other big gainers: MANE, ORKA, OGN, XE, PLBL, SLS, ANAB, EVH, IHRT, RPAY,…- benzinga.com Oppenheimer Maintains Outperform on Evolent Health, Lowers Price Target to $6 Oppenheimer analyst Michael Wiederhorn maintains Evolent Health (NYSE:EVH) with a Outperform and lowers the price target from $12 to $6.
- benzinga.com Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $4 Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $6 to $4.
- benzinga.com UBS Maintains Buy on Evolent Health, Lowers Price Target to $5 UBS analyst Kevin Caliendo maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $10 to $5.